Aspire Biopharma Holdings (ASBP) Non-Current Deffered Revenue (2022 - 2024)

Aspire Biopharma Holdings (ASBP) has reported Non-Current Deffered Revenue for 3 consecutive years, with $5.0 million the latest figure, recorded in Q4 2024.

• On a quarterly basis, Non-Current Deffered Revenue fell 53.76% year-over-year to $5.0 million in Q4 2024; TTM through Dec 2024 was $5.0 million, a 53.76% decrease from a year earlier, with the FY2024 full-year figure at $5.0 million, down 53.76% from the prior year.
• Non-Current Deffered Revenue was $5.0 million for Q4 2024 at Aspire Biopharma Holdings, down from $10.8 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $10.8 million in Q1 2022 and troughed at $5.0 million in Q2 2022.
• A 3-year average of $7.6 million and a median of $5.0 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue changed 0.0% in 2023 and tumbled 53.76% in 2024, its largest moves.
• Over 3 years, Non-Current Deffered Revenue stood at $10.8 million in 2022, then changed by 0.0% to $10.8 million in 2023, then plunged by 53.76% to $5.0 million in 2024.
• The last three Non-Current Deffered Revenue figures came in at $5.0 million (Q4 2024), $10.8 million (Q4 2023), and $5.0 million (Q3 2023), per Business Quant data.